Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

99 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study.
Visentin A, Mauro FR, Scarfò L, Gentile M, Farina L, Reda G, Ferrarini I, Proietti G, Derenzini E, Cibien F, Vitale C, Sanna A, Pietrasanta D, Marchetti M, Murru R, Rigolin GM, Sportoletti P, Trimarco V, Cavarretta CA, Angotzi F, Cellini A, Ruocco V, Zatta I, Laurenti L, Molica S, Coscia M, Ghia P, Foà R, Cuneo A, Trentin L. Visentin A, et al. Among authors: derenzini e. Am J Hematol. 2023 Sep;98(9):E237-E240. doi: 10.1002/ajh.27009. Epub 2023 Jun 29. Am J Hematol. 2023. PMID: 37382471 Free article. No abstract available.
Combined therapy with ibrutinib and bortezomib followed by ibrutinib maintenance in relapsed or refractory mantle cell lymphoma and high-risk features: a phase 1/2 trial of the European MCL network (SAKK 36/13).
Novak U, Fehr M, Schär S, Dreyling M, Schmidt C, Derenzini E, Zander T, Hess G, Mey U, Ferrero S, Mach N, Boccomini C, Böttcher S, Voegeli M, Cairoli A, Ivanova VS, Menter T, Dirnhofer S, Scheibe B, Gadient S, Eckhardt K, Zucca E, Driessen C, Renner C. Novak U, et al. Among authors: derenzini e. EClinicalMedicine. 2023 Sep 22;64:102221. doi: 10.1016/j.eclinm.2023.102221. eCollection 2023 Oct. EClinicalMedicine. 2023. PMID: 37781158 Free PMC article.
Germline BRCA pathogenic variants and hematologic adverse events in patients with ovarian carcinoma receiving PARP inhibitors: a retrospective cohort study.
Valenza C, Nicolò E, Mongillo M, Trapani D, Katrini J, Boldrini L, Boscolo Bielo L, Castellano G, Guidi L, Pellizzari G, Villa J, Derio S, Lapresa M, Gigli F, Parma G, Omodeo Salè E, Derenzini E, Curigliano G, Colombo N. Valenza C, et al. Among authors: derenzini e. Oncologist. 2024 Nov 28:oyae330. doi: 10.1093/oncolo/oyae330. Online ahead of print. Oncologist. 2024. PMID: 39607864 Free article.
Hairy cell leukemia with an atypical extranodal presentation: A clinicopathological analysis of four cases.
Sangiorgio V, Palasciano A, Tabanelli V, Giné E, Guerra L, Pagni F, Casiraghi A, Casaroli I, Frigola G, Magnano L, Gambacorti-Passerini C, Derenzini E, Vanazzi A, Campo E. Sangiorgio V, et al. Among authors: derenzini e. Hum Pathol. 2024 Oct;152:105651. doi: 10.1016/j.humpath.2024.105651. Epub 2024 Aug 28. Hum Pathol. 2024. PMID: 39214241 No abstract available.
Germline BRCA pathogenic variants in patients with ovarian cancer and post-poly (ADP-ribose) polymerase inhibitor myeloid neoplasms.
Valenza C, Mongillo M, Gigli F, Trapani D, Katrini J, Nicolò E, Boldrini L, Boscolo Bielo L, Castellano G, Guidi L, Pellizzari G, Derio S, Lapresa M, Parma G, Derenzini E, Curigliano G, Colombo N. Valenza C, et al. Among authors: derenzini e. ESMO Open. 2024 Sep;9(9):103685. doi: 10.1016/j.esmoop.2024.103685. Epub 2024 Aug 29. ESMO Open. 2024. PMID: 39214046 Free PMC article.
Identification of Novel Potential Predisposing Variants in Familial Acute Myeloid Leukemia.
Ronchini C, Gigli F, Fontanini M, Furgi R, Amato V, Giglio F, Gregato G, Bertolini F, Rondoni M, Lanza F, Billio A, Derenzini E, Tarella C, Pelicci PG, Alcalay M, Todisco E. Ronchini C, et al. Among authors: derenzini e. Cancer Rep (Hoboken). 2024 Aug;7(8):e2141. doi: 10.1002/cnr2.2141. Cancer Rep (Hoboken). 2024. PMID: 39118233 Free PMC article.
High-dose chemotherapy and autologous stem cell transplant as first salvage treatment for relapsed or refractory Hodgkin Lymphoma in the era of PET-adapted strategies.
Viviani S, Vanazzi A, Frassoni S, Rusconi C, Rossi A, Romano A, Patti C, Schiavotto C, Sorasio R, Marasco V, Lissandrini L, Rapezzi D, Gottardi D, Cocito F, Mulè A, Leotta S, Gini G, Sorio M, Derenzini E, Rambaldi A, Bagnardi V, Tarella C. Viviani S, et al. Among authors: derenzini e. Leuk Lymphoma. 2024 Apr;65(4):460-471. doi: 10.1080/10428194.2023.2298273. Epub 2024 Jan 2. Leuk Lymphoma. 2024. PMID: 38164812
Non-hepatosplenic extramedullary manifestations in patients affected by Chronic myelomonocytic leukemia. Case report and meta-analysis of the published series.
Maraglino AME, Amato V, Sammassimo S, Gigli F, Tabanelli V, Pastano R, Tarella C, Giglio F, Derenzini E. Maraglino AME, et al. Among authors: derenzini e. Leuk Lymphoma. 2023 Oct;64(10):1719-1722. doi: 10.1080/10428194.2023.2234524. Epub 2023 Jul 14. Leuk Lymphoma. 2023. PMID: 37450318 No abstract available.
[18 F]-FDG PET radiomic model as prognostic biomarker in diffuse large B-cell lymphoma.
Travaini LL, Botta F, Derenzini E, Lo Presti G, Ferrari ME, Airò Farulla LS, Radice T, Mazzara S, Tarella C, Pileri S, Raimondi S, Ceci F. Travaini LL, et al. Among authors: derenzini e. Hematol Oncol. 2023 Oct;41(4):674-682. doi: 10.1002/hon.3171. Epub 2023 May 20. Hematol Oncol. 2023. PMID: 37209024 Free article.
99 results